Nonetheless, if older patients with IDC receiving BCS have consistent comorbidities, molecular types (similar hormone receptor status and HER2), the same cancer stages, and similar treatment protocols relative to younger patients, whether adjuvant WBRT should be omitted is unclear. Here, ERBB2 is linked to cancer.